Microbial Metabolites Line

Purchased Product:

3,4-Dihydroxyphenylacetic Acid (3,4-DHPA)

Application Scenario:

• In C57BL/6 mouse Parkinson’s models, 3,4-DHPA was administered via intraperitoneal injection (dose: 50 mg/kg, once daily for 14 consecutive days) to simulate the accumulation of dopamine metabolites in vivo.
• In vitro, SH-SY5Y dopaminergic neurons were treated with 3,4-DHPA at concentrations of 10 μM, 50 μM, and 100 μM for 24 hours to assess cell viability, ROS levels, and synaptic protein expression.
• Metabolite concentrations in tissues and cells were quantified using HPLC, with an average recovery rate of 97% and relative standard deviation (RSD)<3%.

Experimental Results:

• Neuronal survival increased by approximately 18% in the 50 μM treatment group, and ROS levels decreased by 22%.
• Synaptic protein expression (Synapsin-1) increased by around 15% compared to the control group.
• In behavioral tests, motor coordination (rotarod test) improved by approximately 20%.

Customer Feedback:

"The 3,4-Dihydroxyphenylacetic Acid provided by Alfa Chemistry showed stable and reliable performance in both neuronal models and mouse experiments, providing a solid data foundation for mapping key metabolic pathways."

Purchased Product:

Taurine

Application Scenario:

• During formulation development, taurine was combined with caffeine (50 mg/100 mL) and B vitamins.
• ATP levels and lactate accumulation were evaluated in vitro using C2C12 muscle cells, with taurine concentrations set at 5 mM, 10 mM, and 20 mM.
• Small-scale sensory testing and stability assessment: products were stored at 4°C, 25°C, and 37°C for 30 days, and solubility and content changes were measured.

Experimental Results:

• ATP levels increased by approximately 25% in the 10 mM taurine group, while lactate accumulation decreased by 18%.
• Taurine content remained >98% across all storage temperatures, with good solubility.
• Sensory testing showed a 15% increase in flavor score compared to the control group.

Customer Feedback:

"Alfa Chemistry’s taurine helped us optimize our formulation, enhancing the functionality and stability of our beverages while shortening the development cycle."

Purchased Product:

β-Nicotinamide Mononucleotide (β-NMN)

Application Scenario:

• In vitro experiments: Mouse fibroblasts were treated with 0.5 mM, 1 mM, and 2 mM β-NMN for 48 hours.
• In vivo experiments: C57BL/6 mice were orally administered β-NMN (300 mg/kg/day) for 28 consecutive days.
• Monitored parameters included NAD+ levels (measured by LC-MS), mitochondrial respiration rate (Seahorse analysis), and ROS production (fluorescent dye assay).

Experimental Results:

• In the 1 mM treatment group, cellular NAD+ levels increased by approximately 35%, maximal mitochondrial respiration increased by 28%, and ROS levels decreased by 20%.
• In mice, NAD+ levels in blood and liver tissues increased by approximately 40%, and exercise performance (running wheel distance) improved by 22%.
• All experiments had RSD<5%, ensuring high reproducibility.

Customer Feedback:

"Alfa Chemistry’s β-NMN showed consistent and reliable performance across multiple experimental models, providing critical support for our NAD+ and anti-aging research."